Omentopexy With Glubran®2 for Reducing Complications After Sleeve Gastrectomy
Omentopexy With Glubran®2 for Reducing Complications After Laparoscopic Sleeve Gastrectomy: Results of a Prospective Study.
BACKGROUND. Gastric fistulas, bleeding, and strictures are commonly reported after laparoscopic sleeve gastrectomy (LSG), that increase morbidity and hospital stay and may put the patient's life at risk. This trial reports our prospective evaluation of application of synthetic sealant, a modified cyanoacrylate (Glubran®2), on suture rime, associated with omentopexy, to identify results on LSG-related complications.
METHODS. Patients were enrolled for LSG by two Bariatric Centers, with high-level activity volume. Intraoperative recorded parameters were: operative time, estimated intraoperative bleeding, conversion rate. Presence of early complications after LSG during the follow up period was evaluated. Overall complications were analyzed. Perioperative data and weight loss were also evaluated. A control group was identified for the study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The prospective randomized trial is designed with the aim to verify the effectiveness of the Glubran®2 used in its spray application, according to manufacturer's indications, to perform the omentopexy of the staple line to prevent and reduce early complications after LSG. single-blind randomization was explained: a single surgeon, in enrollment phase, assigned patient to case or control group, after adequate communication of randomization to all patients. The surgeon that performed procedure only knew if patient was randomized to case group (LSG with omentopexy with Glubran®2) or to control group (LSG without omentopexy with Glubran®2). Control group was identified for the study with simple randomization, considering patients treated with LSG during same period. Patients of case and control groups were not paired. Same recording was performed for both groups. Patients were enrolled for LSG by two Bariatric Centers, with high-level activity volume, after multidisciplinary evaluation: inclusion criteria, according with international guidelines, was body mass index (BMI) of greater than 40 kg/m2 or > 35 with at least one co-morbidity, such as hypertension, dyslipidemia or diabetes, age ≥ 18 years old, medically unfit for surgical intervention, absence of active gastric disease, of uncontrolled medical or psychiatric conditions, and signed informed consent. Bariatric procedure was performed according with standardized four-trocars technique. All surgeons involved had a proved experience for bariatric surgery, and have completed learning curve.
The size of the boogie to be used for calibration ranged from 42 to 48 Fr, among two groups. In case group, after gastric partition and confirming correct closure of mechanical section (performed with Endo-Gia, varying depth of stapler, from 3.5 mm blue to 4.4 black charge, according with gastric level), a layer of the synthetic sealant on all rime suture was applied and an omentum flap to place was apposed. Absence of gastric rotation with omentum flap, or any tension on the resected stomach was carefully controlled. In control group, we reinforced staple line with buttressing (bovine pericardium) of mechanical stapler, or with running suture of the rime alone, indifferently. A recording of type of reinforcing was performed, also if not pertinent to study.
Anthropometric data recorded were: age, weight, BMI, presence of comorbidities. Intraoperative recorded parameters were: operative time, estimated intraoperative bleeding (in ml), conversion rate. We prospectively evaluated the presence of early complications after LSG during the follow up period (30 days from intervention). Considered complications were staple line leakage/gastric fistula, postoperative bleeding, intraabdominal abscess, cardiopulmonary failure, and all other complications. In order to considering effects and real impact of mentioned events, we also evaluated length of hospital stay, rate of readmission, rate of reintervention, overall mortality at 30 days. Weight loss was recorded at 15 and 30 days, as excess weight loss percent (EWL%) and as reduction of BMI.
The demographic data and perioperative data were compared using the student's t and Mann- Whitney U tests for continuous variables. Fisher's exact test was used to determine any statistical significance for the categorical variables. The continuous variables were presented as mean ± standard deviation and the categorical variables were presented as the number (%). The level of significance was set at 0.05.
All procedures involving human participants were in accordance with the Ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- body mass index (BMI) of greater than 40 kg/m2 or > 35 with at least one co-morbidity, such as hypertension, dyslipidemia or diabetes,
- age ≥ 18 years old,
- medically unfit for surgical
- absence of active gastric disease, of uncontrolled medical or psychiatric conditions,
- signed informed consent.
Exlusion criteria
- patient not suitable for bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: omentopexy and cyanoacrilate glue
Apposition of omentum with cyanoacrilate glue after gastric section
|
apposition of omentum with cyanoacrilate glue on gastric section
Other Names:
|
|
NO_INTERVENTION: gastrectomy without omentopexy
Gastric section without omentopexy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
fistulization rate
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
bleeding rate
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 110511
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity With BMI >35
-
NCT03943979CompletedObesity, Morbid | Obesity (BMI > 35) and Diabetes Mellitus | Obesity (BMI > 35) and High Blood Pressure | Obesity (BMI > 35) and Dyslipemia
-
NCT07622992Not yet recruitingObesity (BMI > 35) and Diabetes Mellitus | Obesity (BMI > 35) and High Blood Pressure | Obesity (BMI > 35) and Dyslipemia
-
NCT06954844Enrolling by invitationOverweight/Obesity (BMI: 27 and 35 kg/m2)
-
NCT07457034Not yet recruitingBariatric Surgery | Obesity (BMI > 35)
-
NCT07476599Not yet recruiting
-
NCT07528677Not yet recruitingDifficult Airway | Difficult Airway Intubation | Difficult Mask Ventilation | Obesity (BMI > 35)
-
NCT02938117Unknown
-
NCT05126108CompletedNon-morbidly Obese Patients (BMI<35) | Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube | Thyroid and Parathyroid Surgery
-
NCT03974139RecruitingObesity Without Type 2 Diabetes, With BMI>30
-
NCT00578500UnknownFemale Patients Aged 5-35 Prior to Systemic Chemotherapy | With Significant Risk of Ovarian Toxicity
Clinical Trials on omentopexy with cyanoacrilate glue
-
NCT07590206Completed
-
NCT06811623CompletedPediatric Obesity | Morbid Obesity | LAP
-
NCT04994665Recruiting
-
NCT06211699CompletedPostoperative Complications | Bleeding | Postoperative Nausea and Vomiting
-
NCT07426835Recruiting
-
NCT04900740RecruitingAdult Patients With Mid-term or Long-term Venous Access
-
NCT01669837Completed
-
NCT05781932CompletedSuture Techniques | Medical Glue
-
NCT07565038CompletedSleeve Gastrectomy | Reinforcement of Staple Line by Titanium Clips | Reinforcement of Staple Line by Suturing, Omentopexy Over Staple Line